The Cancer Letter’s coverage of power morcellation named a finalist in the 2015 Best in Business Awards for Outstanding Business Journalism

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Matthew Ong, associate editor of The Cancer Letter, was selected as a finalist in the 2015 Best in Business Awards for Outstanding Business Journalism.

The Society of American Business Editors and Writers recognized Ong’s series, “How Medical Devices Do Harm,” as the first runner up in the Print Weeklies/Biweeklies Investigative category. In a two-year investigation, Ong examined how doctors, hospitals, and manufacturers can, as a practical matter, conceal the fact that a device has caused harm and allow adverse outcomes to go unreported. The controversy, which stemmed from an initial focus on power morcellators and FDA regulation of medical devices, has become the focus of investigations launched by Congress, FBI and the Government Accountability Office.

“The Cancer Letter’s coverage of dangerous medical devices provided an important public service by examining the problems that arise with these devices and the regulatory lapses that helped these problems develop,” the judges noted. “The Cancer Letter covered incremental developments over a lengthy period, but also took the time to step back and do necessary big-picture stories on the issue.”

Ong previously won three first place awards, from the National Press Club, the Society of Professional Journalists, and the Washington, D.C. Professional Chapter of the Society of Professional Journalists, for his 2014 coverage of the controversy over power morcellation (The Cancer Letter, July 2, 2015).

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login